Polls and Policy: Signals or Substance
Menée aux Etats-Unis par enquête auprès de 326 patients atteints de cancer, 250 oncologues et 891 participants en population générale, cette étude analyse leurs perceptions relatives à des mesures de contrôle des dépenses dans les programmes Medicare et Medicaid
Costs of cancer care in the United States are projected to rise from $124.6 billion in 2010 to approximately $174 billion in 2020, contributing to an emerging consensus that health care spending is on an unsustainable trajectory.1 With the annual cost of novel therapies often exceeding twice the US median household income of $50,000, access to quality care for individual patients is threatened. Costs of care can lead to financial distress and even bankruptcy.2,3 For the health system as a whole, health care spending consumes a growing proportion of federal and state budgets. Rising costs threaten the viability of public health insurance programs, including Medicare and Medicaid, as well as spending on other social priorities, including cancer research. Controlling costs while improving access to quality care and continuing to support innovation thus poses a critical challenge (....)
Journal of Clinical Oncology , éditorial, 2015